Skip to Content

Novel Therapeutic Agents for the Treatment of Autoimmune Diseases

By Vibeke Strand, David L. Scot, Lee S. Simon

CRC Press – 1996 – 332 pages

Purchasing Options:

  • Add to CartHardback: $231.00
    978-0-8247-9748-5
    September 19th 1996

Description

Provides a detailed survey of therapies for autoimmune diseases, exploring the rationale for their use and clinical data regarding their potential benefit.

Contents

Introduction

The Evaluation of Biological Agents, Vibeke Strand and David L. Scott

Cellular Targeted Therapies

Anti-CD5 Ricin A Chain Immunoconjugate Therapy in Rheumatoid Arthritis, John J. Cash

Early Clinical Studies of IL-2 Fusion Toxin in Patients with Severe Rheumatoid Arthritis

Recent-Onset Insulin-Dependent Diabetes Mellitus, and Psoriasis, Thasia G. Woodworth and Karen Parker

Chimeric Anti-CD4 Antibody as a Potential Therapeutic Agent for Rheumatoid Arthritis, Larry W. Moreland and William J. Koopman

CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis, F. C. Breedveld

The Use of CE9.1, a Primatized Monoclonal Anti-CD4, in the Treatment of Rheumatoid Arthritis, David E. Yocum, Alan M. Solinger, and John Lipani

CAMPATH-1H Therapy in Autoimmune Diseases, Richard A. Watts and John D. Isaacs

CAMPATH-1H in Rheumatoid Arthritis: United States Experience, David E. Yocum and Jeffrey M. Johnston

Cytokine Targeted Therapies

Interferon-Gamma in the Treatment of Rheumatoid Arthritis, Eric M. Veys, Herman Mielants, and Gust Verbruggen

Tumor Necrosis Factor Blockade in Rheumatoid Arthritis, Michael J. Elliott, Marc Feldmann, and Ravinder N. Maini

Engineered Human Anti-Tumor Necrosis Factor-Alpha (TNFaAntibody, CDP571, in Rheumatoid Arthritis, Ernest H. S. Choy and Gabriel S. Panayi

Clinical Experience with Recombinant Human Interleukin-1 Receptor Type I (Rhu IL-1RI) in Patients with Rheumatoid Arthritis, Richard M. Pope, Barbara Drevlow, Jennifer Capezio, Rosa Lovis, and Alan Landay

Treatment of Rheumatoid Arthritis with Soluble Tumor Necrosis Factor Receptor, Gary R. Margolies, William J. Koopman, and Larry W. Moreland

Adhesion Molecule Targeted Therapies

Treatment of Rheumatoid Arthritis with a Monoclonal Antibody to Intercellular Adhesion Molecule-1, Arthur F. Kavanaugh and Peter E. Lipsky

Potential Antigen-Specific Therapies

T-Cell-Receptor Peptide Therapy for Multiple Sclerosis, Arthur A. Vanderbark, Dennis N. Bourdette, Ruth H. Whitham, and Halina Offner

T-Cell Receptor Peptide Vaccination Studies in Rheumatoid Arthritis, Louis W. Heck, Larry W. Moreland, and William J. Koopman

Oral Tolerance for the Treatment of Autoimmune Disease, David A Hafler and Howard L. Weiner

Oral Tolerance, David E. Trentham

Intravenous Immunoglobulin (IVIg) in the Treatment of Autoimmune Diseases, Vibeke Strand and Martin L. Lee

Purine and Pyrimidine Synthesis Inhibitors

Inhibitors of De Novo Nucleotide Synthesis in the Treatment of Rheumatoid Arthritis, Robert I. Fox and Randall E. Morris

Leflunomide: A New Immunosuppressive Drug, David L. Scott and Vibeke Strand

Future Directions

An Assessment of Novel Agents in the Treatment of the Rheumatic Diseases, Vibeke Strand and Lee S. Simon

Name: Novel Therapeutic Agents for the Treatment of Autoimmune Diseases (Hardback)CRC Press 
Description: By Vibeke Strand, David L. Scot, Lee S. Simon. Provides a detailed survey of therapies for autoimmune diseases, exploring the rationale for their use and clinical data regarding their potential benefit.
Categories: Pharmaceutical Medicine, Immunology